Showing results (161-170 of 382) with videos related to
Sort By:
Pageof 39
Archives of Pathology & Laboratory Medicine|July 1, 2026
Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: Insights From Clinical Practice Into Scoring Criteria, Histologic Subtypes, and Genomic Characteristics Across Disease SitesSwati Bhardwaj, Eli Morris, Aditya Halthore, et al.Cancer Immunology Research|October 21, 2017
Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T CellsBrian M Olson, Melissa Gamat, Joseph Seliski, et al.European Journal of Immunology|April 15, 2010
Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4Seng-Ryong Woo, Nianyu Li, Tullia C Bruno, et al.The Journal of Pathology. Clinical Research|February 19, 2025
Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cellsBurles A Johnson, Vamsi Parimi, Sonia Kamanda, et al.The Journal of Urology|May 16, 2022
Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder CancerMax Kates, Ahmed M Mansour, Donald L Lamm, et al.Journal for Immunotherapy of Cancer|October 27, 2019
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibitionWendy Mao, Ali Ghasemzadeh, Zachary T Freeman, et al.World Journal of Urology|April 29, 2019
Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumorOudai Hassan, Belkiss Murati Amador, Kara A Lombardo, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 10, 2009
LAG-3 regulates plasmacytoid dendritic cell homeostasisCreg J Workman, Yao Wang, Karim C El Kasmi, et al.Blood|October 3, 2007
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cellsPaul E Zarek, Ching-Tai Huang, Eric R Lutz, et al.The Journal of Urology|March 25, 2026
UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION TrialSandip M Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, et al.Pageof 39